Nesbuvir (Synonyms: HCV-796)

Name: Nesbuvir
Brand: MedChemExpress
SKU: HY-14775
Rating: 5.0 (6 reviews)

Cat. No.: HY-14775 Purity: 99.21%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

For research use only. We do not sell to patients.

Nesbuvir Chemical Structure

CAS No. : 691852-58-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 319	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 319	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 290	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 390	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 990	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 1300	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

6 Publications Citing Use of MCE Nesbuvir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

IC₅₀ & Target

EC50: 9 nM (NS3^V170A), 13 nM (NS3^V170A), 15 nM (NS3^K583T), 13 nM (NS5B^I424V)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Huh-5-2	CC₅₀	> 33 μM Compound: HCV 796 benzofuran	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	[PMID: 18625766]
Huh-5-2	EC₅₀	0.019 μM Compound: HCV 796 benzofuran	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	[PMID: 18625766]
Huh-7	CC₅₀	> 20 μM Compound: HCV-796	Cytotoxicity against human HuH7 cells expressing luciferase reporter gene after 3 days by WST-8 assay Cytotoxicity against human HuH7 cells expressing luciferase reporter gene after 3 days by WST-8 assay	[PMID: 24900815]
Huh-7	EC₅₀	0.0032 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 5a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.017 μM Compound: HCV-796	Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human HuH7 cells after 3 days by luciferase reporter gene assay	[PMID: 18285474]
Huh-7	EC₅₀	0.038 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.042 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.051 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 3a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.055 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 2b in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.069 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus isolate Con1 transfected with NS5B polymerase of HCV genotype 4a infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.13 μM Compound: NNI4, HCV-796	Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay Antiviral activity against Hepatitis C virus genotype 2a JFH1 infected in human Huh7.5 cells assessed as decrease in viral RNA replication after 3 days by hRLuc reporter gene assay	[PMID: 18694956]
Huh-7	EC₅₀	0.35 μM Compound: HCV-796	Antiviral activity against HCV1b infected in human HuH7 cells expressing luciferase reporter gene assessed as reduction of luciferase activity after 3 days Antiviral activity against HCV1b infected in human HuH7 cells expressing luciferase reporter gene assessed as reduction of luciferase activity after 3 days	[PMID: 24900815]
Huh-7	EC₅₀	100 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316N mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316N mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	114 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C445F mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C445F mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	13 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V170A mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V170A mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	13 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B I424V mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B I424V mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	1300 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1b harboring S365T mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1b harboring S365T mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	1335 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring V170A and C316Y mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring V170A and C316Y mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	14 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	15 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 K583T mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 K583T mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	18 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	1900 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1a harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1a harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	1936 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C316Y mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS5B C316Y mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	2.4 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	22 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 G282S mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 G282S mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	2459 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 uM HCV-796 and 400 nM boceprevir by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 uM HCV-796 and 400 nM boceprevir by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	2500 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316F mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316F mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	25680 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring C316Y and C445F mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring C316Y and C445F mutations mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	27 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	3368 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis	[PMID: 18936191]
Huh-7	EC₅₀	38 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 E176G mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 E176G mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]
Huh-7	EC₅₀	420 nM Compound: 1	Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay Antiviral activity against wild type Hepatitis C virus genotype 1b harboring C316Y mutant infected in human HuH7 cells assessed as inhibition of viral replication after 72 hrs by Bright-glo luciferase reporter gene assay	[PMID: 23672667]
Huh-7	EC₅₀	9 nM Compound: HCV-796	Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V158M mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay Antiviral activity against Hepatitis C virus genotype 1b Con1 harboring NS3 V158M mutant infected in human HuH7.5 cells after 72 hrs by gaussia luciferase reporter assay	[PMID: 18936191]

In Vitro

Replicon cells are treated with 1 mg/mL G418 and combinations of the two compounds. Nesbuvir (HCV-796) is added to 40 or 80 nM (approximately 10 and 20 times the EC₅₀ in a 3-day replicon inhibition assay, respectively) and Boceprevir is added to 400 or 800 nM (approximately 2 and 4 times the EC₅₀, respectively). The EC₅₀s for Nesbuvir and Boceprevir for the parental replicon in the transient expression assay are comparable to those obtained in the 3-day inhibition assay with the stable replicon cells; the EC₅₀ for Nesbuvir in the transient expression assay is 14 nM, whereas it is 5 nM for the stable replicon; and the EC₅₀ for Boceprevir in the transient expression assay is 608 nM, whereas it is 201 nM for the stable replicon^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Among a huge variety of yet characterized nucleoside and non-nucleoside inhibitors (NNI), the benzofurane derivative NNI Nesbuvir (HCV-796) is demonstrated to yield significant antiviral effects in mice with chimeric human livers and in patients infected with HCV. HCV-796 binds to a hydrophobic binding pocket at the “palm” domain of NS5B; however, its mode of inhibition remains to be defined^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

446.49

Formula

C₂₂H₂₃FN₂O₅S

CAS No.

691852-58-1

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=C(C2=CC=C(F)C=C2)OC3=CC(N(CCO)S(=O)(C)=O)=C(C4CC4)C=C13)NC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (111.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2397 mL	11.1985 mL	22.3969 mL
5 mM	0.4479 mL	2.2397 mL	4.4794 mL
10 mM	0.2240 mL	1.1198 mL	2.2397 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.21%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (253 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Flint M, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother. 2009 Feb;53(2):401-11. [Content Brief]

[2]. Reich S, et al. Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem. 2010 Apr 30;285(18):13685-93. [Content Brief]

Cell Assay
^[1]

Huh7-BB7 cells are seeded at a density of 20,000 cells per 100 mm dish in DMEM supplemented with 2% FBS, 1 mg/mL G418, and various concentrations of Nesbuvir and/or Boceprevir with DMSO at a final concentration of 0.5% (vol/vol). The medium is removed and is replaced with fresh medium with the appropriate compound concentrations every 3 or 4 days. After 7 days, the cells are split 1 to 10, placed into fresh 100 mm dishes, and incubated with medium with the appropriate compound concentrations. After 20 days, the medium is removed and the cells are fixed with 7% (wt/vol) formaldehyde and stained with 1% (wt/vol) crystal violet in 50% (vol/vol) ethanol^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Flint M, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother. 2009 Feb;53(2):401-11. [Content Brief]

[2]. Reich S, et al. Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem. 2010 Apr 30;285(18):13685-93. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2397 mL	11.1985 mL	22.3969 mL	55.9923 mL
	5 mM	0.4479 mL	2.2397 mL	4.4794 mL	11.1985 mL
	10 mM	0.2240 mL	1.1198 mL	2.2397 mL	5.5992 mL
	15 mM	0.1493 mL	0.7466 mL	1.4931 mL	3.7328 mL
	20 mM	0.1120 mL	0.5599 mL	1.1198 mL	2.7996 mL
	25 mM	0.0896 mL	0.4479 mL	0.8959 mL	2.2397 mL
	30 mM	0.0747 mL	0.3733 mL	0.7466 mL	1.8664 mL
	40 mM	0.0560 mL	0.2800 mL	0.5599 mL	1.3998 mL
	50 mM	0.0448 mL	0.2240 mL	0.4479 mL	1.1198 mL
	60 mM	0.0373 mL	0.1866 mL	0.3733 mL	0.9332 mL
	80 mM	0.0280 mL	0.1400 mL	0.2800 mL	0.6999 mL
	100 mM	0.0224 mL	0.1120 mL	0.2240 mL	0.5599 mL

Nesbuvir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nesbuvir691852-58-1HCV-796HCV796HCV 796HCVHepatitis C virusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Nesbuvir (Synonyms: HCV-796)

Customer Review

Nesbuvir Related Antibodies

6 Publications Citing Use of MCE Nesbuvir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Nesbuvir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Nesbuvir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report